IDE 574
Alternative Names: IDE-574Latest Information Update: 09 Apr 2026
At a glance
- Originator IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors; KAT6B protein inhibitors; KAT7 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 06 Apr 2026 Phase-I clinical trials in Breast cancer (unspecified route) in USA (IDEAYA Biosciences pipeline, April 2026)
- 06 Apr 2026 Phase-I clinical trials in Colorectal cancer (unspecified route) in USA (IDEAYA Biosciences pipeline, April 2026)
- 06 Apr 2026 Phase-I clinical trials in Non-small cell lung cancer (unspecified route) in USA (IDEAYA Biosciences pipeline, April 2026)